Portal hypertension is a common hemodynamic abnormality associated with chronic liver disease. In liver cirrhosis, increased intrahepatic vascular resistance to the portal flow increases portal pressure and results in portal hypertension. Once portal hypertension develops, the splanchnic vasodilation increases portal inflow to worsen portal hypertension (PH), and eventually brings about hyperdynamic circulation.
Compensated cirrhosis displays no obvious and fatal clinical signs, and life quality is satisfactory with a median survival about 12 years in this early stage. Cirrhosis progression can be reverted depending on etiological treatment. With the persistence of liver injury, portal hypertension may progress to clinically significant portal hypertension (HVPG=10 mmHg). Above this level of portal pressure, esophageal varices, and lethal decompensation events (ascites, variceal bleeding, encephalopathy, or jaundice) may develop. The median survival is only 1.8 years in patients who develop decompensation.
The goal of this Research Topic is to provide a platform for potential authors to highlight recent advances in full-course management of cirrhotic portal hypertension research, including basic laboratory studies and clinical trials. We welcome authors to contribute with innovative original articles or critical reviews in this field, including clinical research, basic laboratory techniques, multidisciplinary team-oriented practice, innovation-oriented research, and patient-oriented care, to promote comprehensive management of portal hypertension.
We encourage researchers and clinicians to present cutting-edge research on novel aspects of portal hypertension, and new management strategies in cirrhotic portal hypertension that improve patient outcome. We welcome the submissions of the following subtopics, but not limited to:
• Impact of aetiological therapy on regression of cirrhosis and portal hypertension
• Development, transformation and application of novel screening and diagnosis tools for Cirrhotic Portal Hypertension
• Prevention and management of decompensation in Cirrhotic Portal Hypertension patients
• Management of the acute bleeding episode in Cirrhotic Portal Hypertension patients
Portal hypertension is a common hemodynamic abnormality associated with chronic liver disease. In liver cirrhosis, increased intrahepatic vascular resistance to the portal flow increases portal pressure and results in portal hypertension. Once portal hypertension develops, the splanchnic vasodilation increases portal inflow to worsen portal hypertension (PH), and eventually brings about hyperdynamic circulation.
Compensated cirrhosis displays no obvious and fatal clinical signs, and life quality is satisfactory with a median survival about 12 years in this early stage. Cirrhosis progression can be reverted depending on etiological treatment. With the persistence of liver injury, portal hypertension may progress to clinically significant portal hypertension (HVPG=10 mmHg). Above this level of portal pressure, esophageal varices, and lethal decompensation events (ascites, variceal bleeding, encephalopathy, or jaundice) may develop. The median survival is only 1.8 years in patients who develop decompensation.
The goal of this Research Topic is to provide a platform for potential authors to highlight recent advances in full-course management of cirrhotic portal hypertension research, including basic laboratory studies and clinical trials. We welcome authors to contribute with innovative original articles or critical reviews in this field, including clinical research, basic laboratory techniques, multidisciplinary team-oriented practice, innovation-oriented research, and patient-oriented care, to promote comprehensive management of portal hypertension.
We encourage researchers and clinicians to present cutting-edge research on novel aspects of portal hypertension, and new management strategies in cirrhotic portal hypertension that improve patient outcome. We welcome the submissions of the following subtopics, but not limited to:
• Impact of aetiological therapy on regression of cirrhosis and portal hypertension
• Development, transformation and application of novel screening and diagnosis tools for Cirrhotic Portal Hypertension
• Prevention and management of decompensation in Cirrhotic Portal Hypertension patients
• Management of the acute bleeding episode in Cirrhotic Portal Hypertension patients
